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AbstrACt
Objective Test accuracy of faecal calprotectin (FC) testing 
in primary care is inconclusive. We aimed to assess the 
test accuracy of FC testing in primary care and compare 
it to secondary care estimates for the detection of 
inflammatory bowel disease (IBD).
Methods Systematic review and meta-analysis of test 
accuracy using a bivariate random effects model. We 
searched MEDLINE, EMBASE, Cochrane Library and Web of 
Science until 31 May 2017 and included studies from auto 
alerts up until 31 January 2018. Eligible studies measured 
FC levels in stool samples to detect IBD in adult patients 
with chronic (at least 6–8 weeks) abdominal symptoms in 
primary or secondary care. Risk of bias and applicability 
were assessed using the Quality Assessment of Diagnostic 
Accuracy Studies-2 criteria. We followed the protocol 
registered as PROSPERO CRD 42012003287.
results 38 out of 2168 studies were eligible including 
five from primary care. Comparison of test accuracy by 
setting was precluded by extensive heterogeneity. Overall, 
summary estimates of sensitivity and specificity were 
not recorded. At a threshold of 50 µg/g, sensitivity from 
separate meta-analysis of four assay types ranged from 
0.85 (95% CI 0.75 to 0.92) to 0.94 (95% CI 0.75 to 0.90) 
and specificity from 0.67 (95% CI 0.56 to 0.76) to 0.88 
(95% CI 0.77 to 0.94). Across three different definitions 
of disease, sensitivity ranged from 0.80 (95% CI 0.76 to 
0.84) to 0.97 (95% CI 0.91 to 0.99) and specificity from 
0.67 (95% CI 0.58 to 0.75) to 0.76 (95% CI 0.66 to 0.84). 
Sensitivity appears to be lower in primary care and is 
further reduced at a revised threshold of 100 µg/g.
Conclusions Conclusive estimates of sensitivity and 
specificity of FC testing in primary care for the detection of 
IBD are still missing. There is insufficient evidence in the 
published literature to support the decision to introduce FC 
testing in primary care. Studies evaluating FC testing in an 
appropriate primary care setting are needed.
IntrOduCtIOn 
Inflammatory bowel disease (IBD) is an 
organic disease caused by inflammation of the 
intestine. The disease is severe and progres-
sive,1 2 and over 50% of people require surgery 
within 10 years of diagnosis.3 Timely referral, 
which requires filtering of patients with a high 
probability of IBD from a broader group of 
patients with mainly irritable bowel syndrome 
(IBS), is vital. As many as 3.1 million people in 
the USA4 and 2.5–3 million people in Europe5 
suffer from IBD with close to 300 000 patients 
in the UK.6 An estimated 256 000 new cases 
of IBD are diagnosed annually throughout 
Europe.5 Northern America and Northern 
Europe, including the UK, have the highest 
incidence rates.7 
General practitioners refer between 10% 
and 20% of patients presenting with abdom-
inal symptoms if no specific test is available.8 9 
However, only about 25% of referred patients 
have organic disease, of which one-third have 
IBD.10 11 Faecal calprotectin (FC), a regulator 
of the inflammatory response, could poten-
tially aid more selective referral. Patients with 
high levels of FC have an increased probability 
of IBD. FC is a small calcium-binding protein. 
It is released into the intestinal lumen from 
activated neutrophils accumulating at the 
strengths and limitations of this study
 ► This review used an innovative approach involving 
random combinations of test accuracy data from in-
cluded studies in 25 000 meta-analyses to display 
the breadth of heterogeneous evidence from includ-
ed studies.
 ► Exploratory meta-analyses investigated different 
test assays, clinical questions and positivity thresh-
olds of faecal calprotectin levels.
 ► No overall summary estimates of sensitivity and 
specificity were produced due to heterogeneity.
 ► Comparison of test accuracy by setting was preclud-
ed by extensive heterogeneity in the small number 
of studies in primary care.
 ► The categorisation into different clinical questions 
was subjective because the disease categories are 
ill defined and studies’ definitions of conditions and 
groups of conditions varied.
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site of inflammation, and levels of FC are correlated with 
the level of inflammation.12 The protein is stable at room 
temperature and resistant to digestion, making it a rela-
tively easy candidate for a stool test for inflammation of 
the intestinal tract. 
The FC test is approved by the Food and Drug Admin-
istration and recommended by gastroenterological soci-
eties across the globe for its usefulness in the diagnosis 
of IBD.13–16 However, there is no clear guidance on which 
settings it is considered appropriate. FC testing is not 
supported by Medicare in the USA and Australia, but is 
approved for the differential diagnosis of IBD and IBS 
in adult patients in the UK by the National Institute for 
Health and Care Excellence (NICE) when referral to 
secondary care is being considered and cancer is not 
suspected (DG11).17 At the time of the recommendations, 
only test accuracy studies undertaken in secondary care 
were available to inform the decision.18 Our knowledge 
on how the test performs in primary care is limited and 
a systematic approach to assessing the applicability of the 
available evidence specifically for this setting is timely. We 
aimed to assess the test accuracy of FC testing to detect 
IBD in adult patients with chronic abdominal symptoms 
in a primary care pathway (figure 1). In addition, we 
aimed to explore the differences in FC test performance 
between primary and secondary care.
MethOds
review methods
We followed the protocol by Waugh et al18 registered as 
PROSPERO CRD 42012003287. We considered all studies 
Figure 1 Indicative pathway of faecal calprotectin testing in primary care based on NICE guidelines (DG11) and expert opinion 
for adult patients presenting with chronic abdominal pain to primary care. CRP, C reactive protein; FC, faecal calprotectin; 
IBS, irritable bowel syndrome; NICE, National Institute for Health and Care Excellence; TFT, thyroid function test.
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included by Waugh et al18 for inclusion and searched 
MEDLINE, EMBASE, Cochrane Library and Web of 
Science from 1 September 2012 to 31 May 2017 (online 
supplementary 1). Eligible studies from auto-alerts were 
included up until 31 January 2018. Reference lists of 
included studies were checked.
Studies were assessed for eligibility independently and 
in duplicate, and any disagreements were resolved by 
consensus. Records rejected at full-text stage and reasons 
for exclusion were documented.
We included studies which measured FC levels in 
stool samples to detect IBD in adult patients (with ≥80% 
of study population 18–60 years) with chronic (at least 
6–8 weeks) abdominal symptoms not yet diagnosed in 
primary or secondary care. The reference standard to 
verify FC test outcomes was colonoscopy with histology, 
other imaging technologies and follow-up. Our main 
outcomes of interest were sensitivity and specificity.
Data were extracted by KF on prespecified data 
extraction sheets (online supplementary 2) which were 
checked by HF. For studies reporting sensitivity, speci-
ficity, positive and negative predictive values and a total 
number of included patients, 2×2 tables of true positives, 
false positives (FPs), false negatives and true negatives 
were calculated. For studies reporting test accuracy at a 
lower and an upper cut-off, 2×2 data tables were extracted 
for the lower and the upper cut-off. Authors of relevant 
studies with missing 2×2 data were contacted to request 
data.
Quality was assessed independently and in duplicate by 
two reviewers using the Quality Assessment of Diagnostic 
Accuracy Studies-2 criteria,19 which included definitions 
for the signalling questions to match the review question.
Patient involvement
A patient advisory group was actively involved in the 
funding application for the project of which this study is 
a part. Two representatives of the patient advisory group 
will be involved in dissemination of findings at local and 
national events for patients with IBD.
Analysis
Studies were considered under three main clinical 
questions with different definitions of the target and 
non-target conditions: FC testing to differentiate: (1) 
IBD from IBS, (2) IBD from non-IBD conditions and (3) 
organic from non-organic conditions. Different FC test 
assays were handled independently.
We used Review Manager V.5.3 (The Cochrane Collab-
oration, The Nordic Cochrane Centre, Copenhagen, 
Denmark) to produce paired forest plots of sensi-
tivity and specificity. All analyses were performed in R 
V.3.4.1 (Vienna, Austria).20 Meta-analyses were under-
taken using a bivariate random effects model21 using the 
package glmer22 with a minimum of five studies required 
for meta-analysis. Different assays and clinical ques-
tions were considered separately. No overall summary 
estimates of sensitivity and specificity were produced 
due to heterogeneity. Test accuracy was explored at the 
commonly used thresholds of 50 and 100 µg FC per g 
stool sample (µg/g). Outputs from meta-analyses were 
entered into Review Manager to produce receiver oper-
ating characteristic (ROC) plots.
Heterogeneity was explored by meta-regression analyses 
with assay type and clinical question added as covariates in 
turn. We tested the assumption of equal variances (online 
supplementary 3) suggesting this was reasonable for the 
data set. Additional models assuming unequal variances did 
not converge.
Each meta-analysis considered only one outcome per 
study. However, a number of studies reported 2×2 data 
for multiple test assays and clinical questions. We, there-
fore, undertook an exploratory sensitivity analysis. First, 
we produced a list of all possible combinations of test assay 
and clinical question for each included study at a common 
threshold (some studies reported outcomes for one test 
assay and clinical question contributing one possible 
combination while others reported results for up to three 
test assays and two clinical questions resulting in 6 possible 
combinations). We then ran a random sample of 25 000 
meta-analyses out of a possible 10 million picking one 
outcome per study at random in each round of meta-anal-
ysis and considering all combinations of test assays and clin-
ical questions reported in the studies. Pairs of sensitivity and 
specificity from these meta-analyses were plotted in an ROC 
plot and a two-dimension density plot to take account of the 
different definitions of disease and test assays and to allow 
visualisation of the variability in the data.
results
Figure 2 provides the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses23 flow diagram of study 
selection. See online supplementary 4 for a list of records 
rejected at full-text stage and reasons for exclusion. Out of 
2168 unique records, 38 studies were eligible for inclusion. 
The summary table 1 reveals extensive heterogeneity in all 
major aspects of test accuracy studies. Study characteristics 
by study can be found in online supplementary 5. 
Figure 3 summarises the assessment of risk of bias and 
applicability (online supplementary 6 for the assessment by 
study). Overall, the risk of bias was high or uncertain across 
all four domains in at least 50% of studies. Concerns about 
the applicability of the patient population to a primary care 
setting were high in about 75% of studies. 
The forest plots in online supplementary 7 describe the 
complete evidence on test accuracy from the 38 included 
studies reporting all the thresholds, assays and clinical 
questions explored. Overall, as might be expected, sensi-
tivity decreases and specificity increases as the threshold 
increases. FC testing appears to be more accurate in the 
detection of the more precise clinical construct of IBD 
than in the detection of organic disease as a whole.
Two studies24 25 compared five and six different test 
assays at a common threshold of 50 µg/g. This allows for 
a test comparison in the same study population under 
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similar study conditions. It appears that the specificity 
varies to a greater extent than the sensitivity (figure 4). 
Both studies reported medium to strong correlations but 
low agreement between assays, meaning that analysing 
the same sample with different FC test assays will result in 
different values for FC.
Meta-analysis at 50 µg/g threshold
Out of 38, 28 studies reported test accuracy at the common 
50 µg/g cut-off and could be considered for meta-analysis. 
Meta-analyses were undertaken separately for test assays 
and for clinical questions to explore heterogeneity and 
to allow for multiple outcomes from a number of studies.
All 18 assays were considered in the meta-analysis inves-
tigating effect of assay type on summary estimates of test 
accuracy. (This was based on the assumption that the clin-
ical question is generic and one outcome was picked per 
study for analysis). Four assays (PhiCal, EK-CAL, Quan-
tum-Blue and EliA) with five or more studies each could 
be considered in the comparison (online supplementary 
8 for 2×2 data). Nineteen studies contributed data.10 24–41 
Five studies10 25 31 39 40 contributed data to two different 
assays. Figure 5 depicts the pairs of sensitivity and FP 
rates of contributing studies in the ROC space, with 
summary estimates by assay type. At the global 50 µg/g 
threshold, test performance appeared to vary slightly 
across assays (table 2). Quantum-Blue had the highest 
summary estimate for sensitivity with 0.94 (95% CI 0.75 
to 0.99) but also the lowest specificity (0.67, 95% CI 0.56 
to 0.76). The greatest difference in sensitivity (9%) was 
between EK-CAL ELISA and Quantum-Blue point-of-care 
test (POCT) while the greatest difference in specificity 
(21%) was between PhiCal ELISA and Quantum-Blue 
Figure 2 Flow diagram of study inclusion.
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POCT suggesting greater variation in specificity than in 
sensitivity across assays. Whether these differences are 
due to differing performance of test assays or due to 
methodological issues in study design is difficult to ascer-
tain. The differences are large enough to suggest that test 
assays should not be treated as equivalent.
All reported 2×2 data (online supplementary 9) for the 
clinical questions IBD versus IBS, IBD versus non-IBD and 
organic versus non-organic disease were considered in 
the meta-analysis investigating the effects of the different 
clinical questions on summary estimates of test accuracy 
under the assumption that the test is generic. Twen-
ty-eight studies were included at the common threshold 
of 50 µg/g.10 24–50 A total of 10 studies30 32 34 36 37 43 45–48 
contributed information to more than one category. 
The ROC plot in figure 6 summarises the summary esti-
mates for the comparison of the three clinical questions 
and the pairs of sensitivity and FP rates for the contrib-
uting studies. Table 2 shows that specificity for IBD versus 
non-IBD (0.67, 95% CI 0.58 to 0.75) is lower than for IBD 
versus IBS (0.76, 95% CI 0.66 to 0.84), acknowledging 
that CIs overlap, suggesting that broadening the defi-
nition of the non-target condition may produce more 
FPs as other non-IBD intestinal conditions are included. 
On the other hand, sensitivity for organic disease (0.80, 
95% CI 0.76 to 0.84) is lower than for IBD (0.97, 95% CI 
0.91 to 0.99) suggesting that some organic disease will be 
missed with FC testing as organic conditions, including 
adenomas and diverticulosis, are not typically associated 
Table 1 Summary of study characteristics of included 
studies addressing the test accuracy question of FC testing 
in the detection of IBD
Study characteristic Outcome
Study characteristics:
Publication type (studies)
   Full text 32
   Abstract 6
  Year of publication (range) 2000–2018
  Population size (range) 31–1031
Geographical region (studies):
  UK 14
  Rest of Europe 16
  Asia 2
  Middle East 2
  North Africa 1
  Russia 1
  Canada 1
  USA 1
Patient characteristics:
  Age (range) 14–97 years
  IBD prevalence (range) 2.1%–76%
FC assay type (studies)*:
  Immunoassays
   ELISA 32
   FEIA 5
   CLIA 3
   PETIA 2
  POCT 10
Setting (studies)†
  Primary care 5
  Secondary care 29
   Outpatients and inpatients 12
   Referred patients 17
  Mix 2
Target condition (studies)*:
  IBD 23
  Inflammatory disease 5
  Organic disease 19
Non-target condition (studies)*:
  IBS 12
  Functional disease 2
  Non-IBD 12
  Non-organic disease 16
  Non-inflammatory disease 5
  Other 3
FC test data collection (studies):
  Prospectively for patients with eligible 
symptoms in primary care
1
Continued
Study characteristic Outcome
  Prospectively for patients at time of referral in 
primary care
1
  Retrospectively of routine FC tests in primary 
or secondary care
10
  Prospectively prior to a planned colonoscopy 
in secondary care
23
  Prospectively during the assessment for the 
need of colonoscopy in secondary care
1
  Unclear 2
Reference standard (studies):
  Colonoscopy with biopsy 13
  Colonoscopy±biopsy 7
  Endoscopy+other imaging tests 8
  Endoscopy+follow-up 3
  Endoscopy+other imaging tests+follow-up 5
  Unclear 2
*Some studies evaluated multiple tests/clinical questions.
†Two studies were unclear about the setting.
CLIA, chemiluminescent immunoassay; FC, faecal calprotectin; 
FEIA, fluorescence enzyme immunoassay; IBD, inflammatory 
bowel disease; IBS, irritable bowel syndrome; PETIA, particle-
enhanced turbidimetric immunoassay; POCT, point-of-care 
test. 
Table 1 Continued 
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with inflammation. Considering different definitions of 
the clinical questions results in greater variation in sensi-
tivity than specificity meaning that widening the target 
condition had a greater impact on test accuracy than 
changing the non-target condition (IBS vs non-IBD vs 
non-organic disease).
Meta-analysis at 100 µg/g threshold
Eleven studies30 32 35 43 45–48 51–53 reported test accuracy at 
a threshold of 100 µg/g (online supplementary 10 for 
2×2 data). Of these, five contributed to more than one 
category of clinical questions. As expected raising the 
threshold to 100 µg/g reduces sensitivity and increases 
specificity for all clinical questions (table 2). Insufficient 
numbers of studies at the 100 µg/g were available to 
explore assay type.
Meta-regression and exploratory sensitivity analysis
Results from separate meta-analyses and from meta-re-
gression analyses with equal variances showed similar 
results (table 2 and online supplementary 3).
Ten studies reported results for multiple clinical ques-
tions and eight studies compared multiple tests. Our 
approach of randomly selecting one test or one clinical 
question per study for meta-analysis uses only one set of 
evidence per study. Choosing a different set might have 
resulted in different outcomes and conclusions as the 
meta-analyses suggest that it might not be appropriate 
to consider tests and questions alike. In an attempt to 
capture this variation, figure 7 displays results of 25 000 
meta-analyses of 28 studies (online supplementary 11 for 
2×2 data) picking one outcome per study at random for 
each round of meta-analysis. The results show overall high 
sensitivity and specificity irrespective of test assay and clin-
ical question (Panel A) with slightly greater variation in 
sensitivity than specificity (Panel B). Median sensitivity 
and specificity of the 25 000 analyses and ranges were 
0.9 (min 0.85, max 0.94) and 0.76 (min 0.73, max 0.79), 
respectively.
Primary versus secondary care
Five of the eligible studies were from primary care 
settings.35 44 47 48 53 The studies were too heterogeneous 
for meta-analysis. In an attempt to compare test perfor-
mance of FC testing in primary care with secondary 
Figure 3 Overview of risk of bias and applicability concern of included studies according to QUADAS-2.19 QUADAS-2, Quality 
Assessment of Diagnostic Accuracy Studies-2. 
Figure 4 Forest plot of (A) Oyaert et al24 comparing six FC tests and (B) Labaere et al25 comparing five FC tests at cut-off 
50 µg/g. CLIA, chemiluminescent immunoassay; FC, faecal calprotectin; FEIA, fluorescence enzyme immunoassay; FN, false 
negative; FP, false positive; PETIA, particle-enhanced turbidimetric immunoassay; POCT, point-of-care test; TP, true positive; 
TN, true negative. 
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care only one study qualified.47 The study evaluated the 
routine use of FC testing in primary care and reported 
lower sensitivity of 0.72 but comparable specificity of 0.65 
for differentiating IBD from non-IBD at a threshold of 
50 µg/g when compared with our pooled estimates across 
different test assays including all settings (sensitivity 0.95, 
95% CI 0.88 to 0.98 and specificity 0.67, 95% CI 0.58 to 
0.75). However, indication for testing and the place of 
the FC test in the patient pathway were unclear in this 
study and the study may suffer from differential verifica-
tion bias due to concerns over the reference standard. 
The authors explained the low sensitivity with the fact 
that general practitioners may have referred patients with 
high suspicion of IBD without testing. Another reason-
able explanation could be the greater number of appar-
ently milder IBD cases in primary care in which FC testing 
is falsely negative, reducing sensitivity in this setting and 
demonstrating the impact of the different spectrum of 
disease on test accuracy estimates.54
dIsCussIOn
None of the 38 included studies sufficiently addressed 
the review question of test accuracy of FC testing in a 
primary care pathway. The studies recruited patients 
with a different spectrum of disease from that antici-
pated for primary care, focused on disease groups which 
were broader than the intended IBD group or did not 
verify all patients with the preferred reference standard. 
Furthermore, the evidence was highly heterogeneous. 
Studies varied in thresholds and assays used, as well as 
in target conditions and settings. Eighteen different test 
assays were studied, although similar they could not be 
considered generic for meta-analysis. Clinical questions 
were analysed as three distinct categories which were 
related but which could not be pooled for meta-anal-
ysis. A number of studies compared multiple tests and/
or explored different clinical questions. Picking one test 
and one clinical question per study for meta-analysis was 
unjustifiable. We favoured an innovative approach which 
allowed us to explore the whole breadth of evidence and 
showed that irrespective of clinical question and test 
assay, test accuracy of FC testing was high. However, the 
variation in specificity could translate into considerable 
uncertainty of FPs when scaled up to population testing, 
while the variation in sensitivity reflects the limited value 
of FC testing for other organic conditions.
The review has a number of limitations. Due to hetero-
geneity, we decided not to pool across tests and clinical 
questions. Instead, we conducted exploratory analyses 
which demonstrated that the test assay and clinical ques-
tion may affect the summary sensitivity and specificity by 
as much as 9%. We were also unable to compare primary 
and secondary care studies due to the small number of 
heterogeneous studies in primary care. The meta-regres-
sion analyses assumed equal variances between categories 
of tests and clinical questions and this was supported by 
a statistical comparison. However, the power of this test is 
dependent on the number of studies per subgroup and it 
is possible that this assumption could be challenged with 
a larger data set. Finally, the categorisation into different 
clinical questions was subjective because the disease cate-
gories are ill defined and studies’ definitions of condi-
tions and groups of conditions varied.
This review is broadly in line with the approaches and 
interpretation of the evidence of the previous review.18 
However, Waugh et al reported pooled estimates of sensi-
tivity (0.93, 95% CI 0.83 to 0.97) and specificity (0.94, 
95% CI 0.73 to 0.99) across tests for the differential diag-
nosis of IBD versus IBS for five secondary care studies 
and this was the basis for national decisions to introduce 
FC testing in primary care. When compared with our 
equivalent analysis of 11 studies, we found comparable 
sensitivity (0.97, 95% CI 0.91 to 0.99) but considerably 
lower specificity (0.76, 95% CI 0.66 to 0.84) suggesting 
that FPs might be more of a concern than previously 
concluded. Thus, the predicted reduction in colonosco-
pies and subsequent cost savings may not be realised as 
a result of introducing FC testing into the primary care 
pathway in the UK.18 Furthermore, this review found 
enough disagreement between tests to caution against 
treating tests as equivalent. Issues in homogenisation, 
dilutions and extraction prior to analysis as well as lack 
of standardisation of different assays contribute to these 
differences. Recommended cut-off values would have to 
be determined locally until these issues are resolved.24
None of the primary care studies assessed FC testing 
for the differential diagnosis of IBD versus IBS. The 
comparison of IBD versus non-IBD might reflect the 
Figure 5 Receiver operating characteristic plot of sensitivity 
and specificity by test (filled shapes present summary 
estimates with 95% confidence region). FEIA, fluorescence 
enzyme immunoassay; POCT, point-of-care test. 
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clinical situation for FC testing more accurately, but 
produces more FPs as FC levels might be raised in diver-
ticular disease, coeliac disease, rectal adenocarcinoma, 
non-speciﬁc inﬂammation, and others.35 53 The meaning 
of the additional FPs due to non-IBD inflammatory 
conditions is debatable in the context of clinical practice 
where incidental findings of true disease would not be 
classed as an FP test outcome but would prompt further 
investigations.
NICE recently endorsed a cut-off of 100 µg/g for use in 
primary care in England and Wales, based on a primary 
care study which showed a 43% reduction in FC test posi-
tives compared with a threshold of 50 µg/g.47 We inves-
tigated test accuracy at this cut-off including all settings 
and demonstrated an increase in specificity by at least 
10%, while the magnitude of the resulting decrease in 
sensitivity was more uncertain.
Referral of FC tested patients was consistent in three UK 
primary care studies (41%,53 42%35 and 48%47 with over 
25% of FC negative patients referred. This raises concerns 
about the impact of FC testing on colonoscopy rates as a 
considerable proportion of referred patients with nega-
tive FC levels were further investigated. Inappropriate use 
of FC testing as a screening test rather than to rule out 
IBD has been proposed as an explanation.55 However, the 
number of investigations of referred FC negatives varied 
greatly among the three studies from 19%47 to 46%35 and 
even 71%53 suggesting perhaps unsurprisingly, that the 
number of potentially unnecessary colonoscopies may be 
at least as dependent on secondary care decision-making 
as on the availability of FC testing in primary care.
The applicability of the spectrum of secondary care 
patients to a primary care setting is questionable even 
if studies investigated referred patients. First, general 
practitioners might have tested more patients than 
they referred and, second, patients referred came from 
different pathways including cancer pathways. Conse-
quently, the patient population of the included studies 
resembled a continuum of primary to secondary care 
patients of which only some might plausibly resemble the 
primary care spectrum. Additionally, primary care popu-
lations may be different in different countries, it would, 
Figure 6 Receiver operating characteristic plot of 
sensitivity and specificity by clinical question (filled 
shapes present summary estimates with 95% confidence 
region). IBD, inflammatory bowel disease; IBS, irritable bowel 
syndrome. 
Figure 7 Pairs of sensitivity and specificity of 25 000 meta-analyses of 28 studies picking one outcome per study at random 
for each round of meta-analysis at a threshold of 50 µg/g. (A) Receiver operating characteristic plot, (B) 2D density plot scaled to 
illustrate spread and density (where the highest density represents a probability of 1000/25 000). 2D, two dimensions.
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therefore, be useful to identify those studies which are 
relevant to primary care irrespective of the actual study 
setting, for instance, using tailored meta-analysis.56 57 
Furthermore, the statistical validity of any summary esti-
mates could be evaluated using a recently developed 
cross-validation technique.58 Only five studies recruited 
subjects from primary care populations and analysed the 
general practitioners’ decisions on whether to test and 
whether to refer.35 44 47 48 53 We found lower sensitivity 
for detection of disease in these studies compared with 
meta-analyses of all studies.
Despite the publication of primary care studies since 
the Waugh et al review,18 we are still lacking evidence on 
the defined role of FC testing in the primary care pathway 
for the detection of IBD. This is a concern given that it is 
prescribed by local and national guidance in the UK and 
the roll-out of a national algorithm endorsed by NICE, 
the National Health Service England Chief Scientific 
Officer and the British Society of Gastroenterologists is 
imminent to improve spread and adoption of FC testing 
nationally.59 The decision to introduce FC testing in 
primary care might have been based on overoptimistic 
assessments of potential test accuracy in this setting. 
Evidence for the test accuracy of FC testing in primary 
care which considers the revised cut-off of 100 µg/g is 
needed before any recommendations for use in primary 
care can be made. Potentially, test accuracy studies in 
primary care are hampered because verification of FC 
test outcomes with colonoscopy may not be feasible in all 
tested patients. Therefore, other reference standards for 
assessing the performance of FC testing in primary care 
are also needed.
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